Alastair Mackay
MVF Senior Life Sciences Principal

Alastair Mackay joined the Maryland Venture Fund as Senior Life Sciences Principal in 2013.  In that capacity, he reviews investment opportunities in Maryland-based startups in the Therapeutics, Implantable Medical Device, Diagnostics, Health-IT, Science Tools, and Agriculture sectors.  He also oversees the two dozen companies in the MVF portfolio whose businesses are focused in these areas.  He holds the Fund’s Board Observer seat at CytImmune, GraftWorx, Graybug, Harpoon Medical, and Perceptive Navigation.

For the prior seven years, Mackay provided expert sell-side coverage of public companies in the biotech, life science tools, medical devices, and molecular diagnostics industries for the institutional clients of GARP Research and Securities.  His mandate was to identify and track companies that could fuel sustained earnings growth by developing and marketing high-value products.  From 1996 to 2005, Mackay was a stem-cell scientist at Osiris Therapeutics, where he studied the differentiation of adult human stem cells.  Away from the bench, he wrote grants, contracted outside research, and worked on SOPs and release assays to meet FDA requirements for Osiris’ first IND application.  Mackay’s postdoctoral training was at the Johns Hopkins University School of Medicine, where he cloned and sequenced an essential protein of the chromosome to discover its function.  Mackay earned his PhD at the University of Vermont by studying how asbestos exposure leads to lung cancer. He received a BA from Dartmouth College in Earth Sciences (a field he still loves!).